2024 CASH | Professor XiaoFan Zhu : Immunotherapy Strategy Brings Greater Benefits to Children with ALL
Children with Acute Lymphoblastic Leukemia (ALL) have a five-year overall survival (OS) rate exceeding 90%, but about 20% still experience disease relapse. Treating these relapsed or refractory ALL cases is…